Boston Scientific Will Offer Alternative To Uterine Morcellation With IoGyn Buy
This article was originally published in The Gray Sheet
Boston Scientific already owns a 28 percent stake in the Silicon Valley start-up, and will now acquire the rest of the firm for $65 million. IoGyn’s 510(k)-cleared uterine surgery tool provides an alternative to power morcellation, which is now being discouraged for use in uterine surgery by FDA.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.